Plasmablastic #lymphoma : 2024 update on diagnosis, risk stratification, and management
Free access: doi.org/10.1002/ajh.27…
Including proposed pathophysiology of PBL:
#hemepath #lymsm

Relapsed primary cutaneous follicle-center lymphoma in the lower extremity:
🩸PCFCL presenting on the leg has a less favorable prognosis
🩸Relapses are observed in about 30% of patients, and do not necessarily indicate progressive disease
#hemepath #lymsm #pathtwitter #dermpath

Our CU Lymphoma Program T-cell expert Dr. Brad Haverkos contributed to a multicenter study of CAR-T for patients with DLBCL in complete remission at time of CAR infusion, now published Leukemia Journal. #lymsm #celltherapy
nature.com/articles/s4137…

Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management |American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10… #lymsm

Relapsed classic Hodgkin lymphoma (CHL) with brighter PAX5 expression then typically accepted for CHL, and associated new emerging follicular lymphoma in the same lymph node biopsy (bottom right of Figure 1) #hemepath #lymsm #pathX #MedX #SoMe #Surgpath #MedTwitter #Pathtwitter

Outcomes for DLBCL in CR at time of CAR-T infusion from CIBMTR:
- 134 pts, median 3 LOT
- 2-yr PFS 44%, OS 64%
- no diff in outcomes if PET done <1 vs >1 month before CAR
Outcomes same as active disease. Would be great to study RT v chemo bridging. #lymsm
nature.com/articles/s4137…

Less than 4 weeks until #EHA24 in Madrid🇪🇺🇪🇸 With the abstracts already available, #EHA2024 is going to be a great meeting 👀🎉 Looking forward to discuss new first-line treatment strategies for Hodgkin lymphoma in an exciting educational on Fri 14th June - come join us! #lymsm

#WomenInLymphoma #lymphoma #lymsm

Two favourite #Hodgkin abstracts for upcoming #EHA2024 #lymsm
1. Plattel et al, S227
Serum TARC is an attractive marker - cheap, simple to perform, and prognostic
iPET+/TARC- patients performed similarly to iPET- patients in advanced HL

Was loads of fun talking with Bloodbytes, Anamarija Perry and Payal Sojitra at the #IUCLS24 #lymsm A big shoutout to Michigan Pathology University of Chicago Hematology/Oncology Cc: Lauren Smith, MD, HEC-C BioAscend Soni Smith MD Andrew M. Evens, DO, MBA, MSc Neha Mehta-Shah Kamran Mirza MD PhD - کامران مرزا

2. Hutchings et al, S226

EORTC COBRA study suggesting very early (iPET1+) intensification of AAVD to BrECADD may overcome the adverse prognosis of slower responders (noting relatively poor iPET2+ outcomes in ECHELON 1).

Intriguing results!

#lymsm

Plasmablastic lymphoma: current knowledge and future directions frontiersin.org/journals/immun… #lymsm

📢 Are you interested in joining our interactive discussion on therapies in B-cell malignancies, co-hosted by the Lymphoma Hub and #MultipleMyeloma Hub at European Hematology Association? Attend and receive 1.5 CME credits of EBAH accreditation!

#EHA2024 #lymsm #mmsm #lymphoma

📢 Are you interested in joining our interactive discussion on therapies in B-cell malignancies, co-hosted by the #Lymphoma Hub and Multiple Myeloma Hub at European Hematology Association? Attend virtually or in person and receive 1.5 CME credits of EBAH accreditation!

#EHA2024 #lymsm #mmsm #multiplemyeloma

Targets and treatments in primary CNS lymphoma tandfonline.com/doi/full/10.10… #pcnsl #lymsm

EscBEACOPP vs BreCADD - HD21. Embargoed abstract but title says it all. Looks like efficacy is superior.
#EHA24 #lymsm

#ASH23 Come join us at the outcomes session in lymphoid disorders - exciting updates on CAR-T, associated toxicities and staging in lymphoma and myeloma! Mazie Tsang, MD, MAS, MS #lymsm #mmsm

EXCELLENT OUTCOME OF PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL B CELL LYMPHOMA  TREATED WITH AXICABTAGENE CILOLEUCEL library.ehaweb.org/eha/2024/eha20… #EHA24 #lymsm

Relapsed DLBCL with unusual spindle-cell morphology, reminiscent of follicular dendritic cell sarcoma (FDCS), with diffuse aberrant expression of FDC markers CD21 and CD23 #hemepath #lymsm #surgpath #pathtwitter #pathX #MedTwitter #MedX #MedEd

Large B-cell lymphoma involving the testicle with a germinal center-like phenotype (CD10+BCL6+MUM1-): May occur in < 10% of primary large B-cell lymphoma of the testis, however, it should raise the suspicion of disseminated systemic DLBCL #hemepath #lymsm #surgpath #Pathx #MedX